Abstract 281P
Background
Based on Globocan 2020, prostate cancer is the second most common male cancer worldwide. One of the main treatments for localized prostate cancer patients is definitive radiotherapy. Regarding limited access to intensity modulated radiation therapy and other modern techniques in developing countries, most patients in these countries are still being treated with 3D conformal RT techniques. Considering the fact that there is association between local control and prostate cancer specific mortality, we aimed to investigate the local control in unfavorable intermediate and high risk prostate cancer patients whom underwent definitive radiotherapy with 3D conformal technique.
Methods
50 patients involved in this study. They all were treated by definitive radiotherapy with 3D conformal technique since 2014 in the Radiation Department of Hamadan University of Medical Sciences. The required data was collected through the assessment of patient's' medical records. All patients were treated using a 4-field (Box) 3D technique with a total dose of 70 Gy. Additionally, in all patients, the whole pelvis was covered in the initial phase of treatment (46Gy).
Results
After the median follow up of 45 month 13 treatment failure was seen in the study population. Bio-chemical relapse occurred in 13 patients (26%). Seven patients were found to have local recurrences (14%). Distant failure, all in bone, occurred in 6 patients (12%). The 3year BCR free survival, local failure free survival and metastases free survival were 76%, 88%, and 88% respectively. The most important factor for BCR, distant failure, and overall failure was extension of disease (T stage).
Conclusions
Our results were lower compared to the results announced in the developed countries' center. This indicates that the use of modern radiotherapy techniques has been essential in prostate cancer treatment, both due to the increased treatment effectiveness and the reduction of treatment side effects. It is vital for developing countries to plan their health care policies in a way that improves patients' access to these innovative techniques. And governments should allocate a budget for updating radiotherapy devices in their country's infrastructure planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Bayani.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract